Evolocumab

Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H2O2-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation[1][2][3].

Product Specifications

CAS Number

[1256937-27-5]

Product Name Alternative

AMG 145

UNSPSC

12352203

Target

NF-κB; Ser/Thr Protease; Toll-like Receptor (TLR)

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer; Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/evolocumab.html

Purity

98.40

Solubility

H2O

Smiles

[Evolocumab]

Molecular Weight

(141.8 kDa)

References & Citations

[1]Fala L, et, al. Repatha (Evolocumab) : Second PCSK9 Inhibitor Approved by the FDA for Patients with Familial Hypercholesterolemia. Am Health Drug Benefits. 2016 Mar;9 (Spec Feature) :136-9.|[2]Zhou Q, et al. Protective effect of evolocumab on Müller cells in the rat retina under hyperglycaemic and hypoxic conditions. J Diabetes Complications. 2023 Oct;37 (10) :108593.|[3]Safaeian L, et al. Evolocumab, a PCSK9 inhibitor, protects human endothelial cells against H2O2-induced oxidative stress. Arch Physiol Biochem. 2022 Dec;128 (6) :1681-1686.